Successful anti-CD20 antibody treatment of pemphigus foliaceus after unrelated cord blood transplantation

Herr, Andrée-Laure; Hatami, Afshin; Kokta, Victor; Dalle, Jean‐Hugues; Champagne, Martin A.; Duval, Michel

doi:10.1038/sj.bmt.1704808

Cited by 13 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most were organ-specific ADs such as cytopenias followed by ADs of the thyroid and a few cases of miscellaneous multisystemic AD. The diagnoses of ADs in our cohort are comparable to those after CBT reported in the literature [6][7][8][9][10][11][12] and to ADs after allogeneic HSCT. 1,14 AIHA, ITP, and, more rarely, autoimmune neutropenia have been reported after allogeneic, noncord-blood-derived SCT with an incidence of 3%-4.5% in 3 single-center studies [14][15][16] The published cases have been reviewed recently.…”

Section: Discussionsupporting

confidence: 75%

See 1 more Smart Citation

New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation

Daikeler

Labopin

Ruggeri

et al. 2013

Blood

View full text Add to dashboard Cite

Key Points• Autoimmune diseases do occur after CBT in approximately 5% of patients.• Of these, AIHA or ITP were observed the most often and were treated with prednisone, CSA, and RTX.To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative incidence of ADs after CBT was 5.0% ؎ 1% at 1 year and 6.6% ؎ 1% at 5 years. Patients developing ADs were younger and had more nonmalignant diseases (P < .001). ADs target hematopoietic (autoimmune hemolytic anemia, n ‫؍‬ 20; Evans syndrome, n ‫؍‬ 9; autoimmune thrombocytopenia, n ‫؍‬ 11; and immune neutropenia, n ‫؍‬ 1) and other tissues (thyroiditis, n ‫؍‬ 3; psoriasis, n ‫؍‬ 2; Graves disease, n ‫؍‬ 1; membranous glomerulonephritis, n ‫؍‬ 2; rheumatoid arthritis, n ‫؍‬ 1; ulcerative colitis, n ‫؍‬ 1; and systemic lupus erythematosus, n ‫؍‬ 1). Four patients developed 2 ADs (3 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rheumatoid arthritis). By multivariate analysis, the main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P ‫؍‬ .0001). Hematologic ADs were most often treated with steroids, rituximab, and cyclosporine. With a median follow-up of 26 months (range, 2-91), 6 of 52 patients died as a consequence of ADs. We conclude that CBT may be followed by potentially life-threatening, mainly hematologic ADs. (Blood. 2013;121(6):1059-1064)

show abstract

Section: Discussionsupporting

confidence: 75%

“…6 The most prevalent ADs reported are AIHA, [6][7] Evans syndrome, 8 ITP, 6,9 thyroiditis, 10 and bullous dermatoses (pemphigus and pemphigoid). [11][12] This study was undertaken to characterize the nature, incidence, and risk factors for ADs developing after CBT in a large patient population.…”

Section: Introductionmentioning

confidence: 99%

New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation

Daikeler

Labopin

Ruggeri

et al. 2013

Blood

View full text Add to dashboard Cite

show abstract

“…There are 10 cases of autoimmune blistering diseases after allogeneic stem cell transplantation reported in the literature between 1986 to 2005 (Table I). [9][10][11][12][13][14][15][16][17][18] All of these patients had acute or chronic GVHD before the development of autoimmune bullous diseases. Seven of 10 patients developed BP.…”

Section: Discussionmentioning

confidence: 99%

Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease

Izumi¹,

Fujimoto

Yazawa³

et al. 2007

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…A variety of circulating autoantibodies can be found from 20% to 61% of patients undergoing autologous bone marrow transplant [108–111], and a number of these patients may demonstrate autoantibody-mediated diseases such as myasthenia gravis and autoimmune cytopenias [112] and some cases of oral diseases, such as oral vesiculobullous (pemphigus and pemphigoid) [113–116]. …”

Section: Classification and Related Aspects Of The Oral Pathologiementioning

confidence: 99%

Oral Lesions and Lymphoproliferative Disorders

Castellarin

Pozzato

Tirelli

et al. 2010

Journal of Oncology

View full text Add to dashboard Cite

Lymphoproliferative disorders are heterogeneous malignancy characterized by the expansion of a lymphoid clone more or less differentiated. At the level of the oral cavity, the lymphoproliferative disorder can occur in various ways, most commonly as lymphoid lesions with extranodal externalization, but sometimes, oral lesions may represent a localization of a disease spread. With regard to the primary localizations of lymphoproliferative disorders, a careful examination of the head and neck, oral, and oropharyngeal area is necessary in order to identify suspicious lesions, and their early detection results in a better prognosis for the patient. Numerous complications have been described and frequently found at oral level, due to pathology or different therapeutic strategies. These complications require precise diagnosis and measures to oral health care. In all this, oral pathologists, as well as dental practitioners, have a central role in the treatment and long-term monitoring of these patients.

show abstract

Successful anti-CD20 antibody treatment of pemphigus foliaceus after unrelated cord blood transplantation

Cited by 13 publications

References 9 publications

New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation

New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation

Bullous pemphigoid positive for anti-BP180 and anti-laminin 5 antibodies in a patient with graft-vs-host disease

Oral Lesions and Lymphoproliferative Disorders

Contact Info

Product

Resources

About